Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$9.44
+2.4%
$9.02
$7.11
$11.73
$1.27B1.631.46 million shs699,762 shs
Enhabit, Inc. stock logo
EHAB
Enhabit
$6.75
-2.1%
$9.04
$6.50
$10.90
$341.57M1.72438,104 shs504,840 shs
GRAIL, Inc. stock logo
GRAL
GRAIL
$40.29
+1.4%
$41.84
$12.33
$63.99
$1.45BN/A1.42 million shs551,688 shs
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$17.28
-1.2%
$15.16
$9.90
$27.20
$1.41B0.39904,580 shs608,252 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
-4.36%+0.22%+5.25%+9.63%-18.41%
Enhabit, Inc. stock logo
EHAB
Enhabit
-0.71%+2.69%-27.85%-11.87%-30.80%
GRAIL, Inc. stock logo
GRAL
GRAIL
-2.84%+10.58%-9.62%+6.77%+166.04%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-2.56%+2.58%+19.30%+29.56%+10.56%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
4.039 of 5 stars
3.51.00.00.02.61.74.4
Enhabit, Inc. stock logo
EHAB
Enhabit
2.8399 of 5 stars
3.34.00.00.00.60.02.5
GRAIL, Inc. stock logo
GRAL
GRAIL
0.668 of 5 stars
1.11.00.00.03.00.81.3
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
2.4356 of 5 stars
3.55.00.00.02.70.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
3.00
Buy$13.4041.95% Upside
Enhabit, Inc. stock logo
EHAB
Enhabit
2.50
Moderate Buy$8.7529.73% Upside
GRAIL, Inc. stock logo
GRAL
GRAIL
2.25
Hold$31.50-21.82% Downside
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
2.90
Moderate Buy$37.56117.34% Upside

Current Analyst Ratings Breakdown

Latest EHAB, VRDN, GRAL, and AHCO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/14/2025
GRAIL, Inc. stock logo
GRAL
GRAIL
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$32.00 ➝ $43.00
5/12/2025
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $13.00
5/8/2025
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$14.00 ➝ $13.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$31.00 ➝ $27.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$46.00 ➝ $45.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $38.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $36.00
(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$3.25B0.39$3.72 per share2.54$11.72 per share0.81
Enhabit, Inc. stock logo
EHAB
Enhabit
$1.03B0.33$3.99 per share1.69$10.92 per share0.62
GRAIL, Inc. stock logo
GRAL
GRAIL
$125.60M11.54$28.37 per share1.42$74.50 per share0.54
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$300K4,699.58N/AN/A$6.09 per share2.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$90.42M$0.5716.569.730.932.63%6.96%2.40%8/5/2025 (Estimated)
Enhabit, Inc. stock logo
EHAB
Enhabit
-$156.20M-$2.77N/A23.26N/A-13.43%2.02%0.94%8/6/2025 (Estimated)
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.03B-$60.99N/AN/AN/A-1,464.53%-17.99%-15.02%8/12/2025 (Estimated)
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$269.95M-$3.85N/AN/AN/A-102,092.39%-70.61%-44.67%8/14/2025 (Estimated)

Latest EHAB, VRDN, GRAL, and AHCO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$1.01N/AN/AN/AN/AN/A
8/12/2025Q2 2025
GRAIL, Inc. stock logo
GRAL
GRAIL
-$3.14N/AN/AN/A$37.57 millionN/A
8/6/2025Q2 2025
Enhabit, Inc. stock logo
EHAB
Enhabit
$0.10N/AN/AN/A$263.39 millionN/A
8/5/2025Q2 2025
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
$0.15N/AN/AN/A$804.97 millionN/A
5/13/2025Q1 2025
GRAIL, Inc. stock logo
GRAL
GRAIL
-$4.03-$3.10+$0.93-$3.10$35.80 million$31.84 million
5/7/2025Q1 2025
Enhabit, Inc. stock logo
EHAB
Enhabit
$0.07$0.10+$0.03$0.35$266.11 million$259.90 million
5/6/2025Q1 2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$0.95-$0.87+$0.08-$0.87$0.16 million$0.07 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
N/AN/AN/AN/AN/A
Enhabit, Inc. stock logo
EHAB
Enhabit
N/AN/AN/AN/AN/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
1.25
1.29
1.07
Enhabit, Inc. stock logo
EHAB
Enhabit
0.82
1.49
1.49
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
9.70
9.71
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
0.05
19.49
19.49

Institutional Ownership

CompanyInstitutional Ownership
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
82.67%
Enhabit, Inc. stock logo
EHAB
Enhabit
N/A
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
1.55%
Enhabit, Inc. stock logo
EHAB
Enhabit
3.40%
GRAIL, Inc. stock logo
GRAL
GRAIL
1.85%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
1.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
AdaptHealth Corp. stock logo
AHCO
AdaptHealth
10,500134.95 million132.86 millionOptionable
Enhabit, Inc. stock logo
EHAB
Enhabit
10,70050.64 million48.92 millionOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
1,36035.97 million35.31 millionOptionable
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
5081.59 million80.30 millionOptionable

Recent News About These Companies

Viridian Therapeutics: The Song Remains The Same

New MarketBeat Followers Over Time

Media Sentiment Over Time

AdaptHealth stock logo

AdaptHealth NASDAQ:AHCO

$9.44 +0.22 (+2.39%)
Closing price 04:00 PM Eastern
Extended Trading
$9.44 0.00 (0.00%)
As of 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.

Enhabit stock logo

Enhabit NYSE:EHAB

$6.74 -0.15 (-2.10%)
Closing price 03:59 PM Eastern
Extended Trading
$6.76 +0.01 (+0.22%)
As of 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.

GRAIL stock logo

GRAIL NASDAQ:GRAL

$40.29 +0.57 (+1.44%)
Closing price 04:00 PM Eastern
Extended Trading
$40.17 -0.12 (-0.29%)
As of 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Viridian Therapeutics stock logo

Viridian Therapeutics NASDAQ:VRDN

$17.28 -0.21 (-1.20%)
Closing price 04:00 PM Eastern
Extended Trading
$17.20 -0.09 (-0.49%)
As of 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.